RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
Video: Healthcare System Readiness in Brain Health
In the final installment of our Brain Health month series, Avalere Health experts examine what it takes to close the gaps between innovation and patient access.
Video: Aduhelm Launch: Lessons for Alzheimer’s Therapies
In this Brain Health Month installment, Avalere Health experts draw lessons from a landmark Alzheimer's launch for manufacturers navigating approval and access.
Beyond R&D: Manufacturers as Partners Enabling Access to Rare Disease Care
In this fifth and final article of our APAC rare disease series, we explore key opportunities for manufacturers to strengthen rare disease healthcare system readiness through multi-stakeholder collaboration.
Video: Spotlight on Women’s Brain Health
In the second installment of our Brain Health Month series, Avalere Health experts discuss key insights from Dr. Roberta Diaz Brinton on menopause, brain health, and emerging opportunities to improve Alzheimer's disease outcomes in women.
Video: Understanding Delphi Panels: Building Expert Consensus
Avalere Health experts break down what a Delphi panel is, how it works, and why its structured methodology sets it apart from a traditional advisory board.
Finding Clarity in Uncertainty: How Delphi Panels Generate Consensus-Driven, Publication-Ready Evidence
Delphi panels are a methodologically rigorous way to fill evidence gaps, build expert consensus, and translate that consensus into meaningful strategic action.
Video: Brain Health Month: Precision Medicine in Alzheimer’s
In the first installment of our Brain Health Month series, Avalere Health experts discuss precision medicine, diagnostics, and patient access in Alzheimer's disease.
Alzheimer’s Treatment Has Changed. Has Value?
Emerging evidence in Alzheimer's disease highlights a gap between measured effects and lived experience, shaping how value is defined, evidenced, and assessed.
Everything We’ve Learned from the RLTs on the Market: The Infrastructure Gap
In the latest installment of our RLT series, we explore the manufacturing, supply chain, infrastructure, and workforce challenges shaping access.
Beyond Plug-and-Play: Elevating HEOR to Enterprise-Level Impact
Successful HEOR teams are increasingly aligning evidence generation strategies with cross-enterprise teams to maximize their impact.
Multi-Stakeholder Collaboration in Rare Diseases: The Role of Clinicians Within and Beyond the Clinic
Clinicians can support timely, sustainable rare disease care through institutionalized multi-disciplinary roles, strengthened referral networks, and the translation of clinical insights into policy and advocacy.
eBook: Rare Disease Biotech Landscape, 2026
Rare disease demands a unique playbook: The patient journey is rarely linear, the evidence base is often limited, and “rare” can have different meanings across settings and geographies. The third edition of our annual rare disease eBook explores the unique dynamics of the rare disease landscape and its implications for biotech stakeholders.
Gene Therapy in Rare Disease: From Breakthrough to Stewardship
As gene therapies for rare diseases scale, system readiness and long-term stewardship–not science alone–will determine access, impact, and sustainability.
Amplifying Rare Disease Patient Groups in APAC
Rare disease patient groups in APAC can amplify their impact through multi-stakeholder collaboration to achieve equitable access for people living with rare diseases.
RWD Integration in Reimbursement Decisions across EU4 and the UK
European countries are advancing real-world data use in healthcare decision-making, but face challenges from differing national frameworks and regulations
Sociodemographic Factors and Healthcare Costs Among Rare Epilepsies
Distinct patient characteristics and cost profiles across rare epilepsies reinforce the value of disease-specific approaches in rare disease research.
Novel Antibiotic Use Is Low, Even for Complex Cases
An Avalere Health analysis determined that less than 1% of patients with community-acquired bacterial pneumonia were treated with novel antibiotics.
Belief Mapping: Elevating Value Engagement Strategies
Uncovering beliefs underpinning payer decision making can help global access teams achieve optimal and equitable patient access, faster.
Healthcare Utilization and Costs for Patients with Transfusion Dependent β-thalassemia Following Luspatercept Use
A retrospective FFS claims analysis of adults with β-thalassemia found limited differences in most related healthcare resource utilization or cost categories before and after luspatercept use among those with transfusion-dependent β-thalassemia.
Unlocking Global Access to GLP-1 AOMs Requires Moving Beyond Disease Recognition to Demonstrating Broader Value
To enable global access to GLP-1 AOMs, manufacturers must demonstrate multidimensional value along the full care continuum and across the range of obesity linked-indications.